Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials (Q64063460)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 May 2019

Language	Label	Description	Also known as
English	Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials	scientific article published on 07 May 2019

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

diastolic blood pressure

0 references

0 references

0 references

systolic blood pressure

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

author name string

Annpey Pong

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Silvina Gallo

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Amanda Darekar

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Steven G Terra

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

language of work or name

0 references

publication date

7 May 2019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Cardiovascular Diabetology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

59

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Comparative analysis of two rates

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Barriers to Blood Pressure Control: A STITCH Substudy

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of Achievement of A1c, Blood Pressure, and Cholesterol (ABC) Goal in Veterans with Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Executive summary: Standards of medical care in diabetes--2012

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of weight loss on pulse wave velocity: systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and Hypertension: A Position Statement by the American Diabetes Association.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clini

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 Inhibitors and Mechanisms of Hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31064361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12933-019-0856-7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31064361%20AND%20SRC:MED&resulttype=core&format=json

24 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64063460&oldid=1751121244"